pharma value demonstration bidco limited
pharma value demonstration bidco limited Company Information
Company Number
12674221
Next Accounts
Sep 2025
Shareholders
value demonstration uk holdings limited
Group Structure
View All
Industry
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
Registered Address
great suffolk yard, 127-131 great suffolk street, london, SE1 1PP
Website
-pharma value demonstration bidco limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA VALUE DEMONSTRATION BIDCO LIMITED at £0 based on a Turnover of £0 and 1.05x industry multiple (adjusted for size and gross margin).
pharma value demonstration bidco limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA VALUE DEMONSTRATION BIDCO LIMITED at £8.7m based on an EBITDA of £2m and a 4.38x industry multiple (adjusted for size and gross margin).
pharma value demonstration bidco limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA VALUE DEMONSTRATION BIDCO LIMITED at £56.8m based on Net Assets of £43.5m and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharma Value Demonstration Bidco Limited Overview
Pharma Value Demonstration Bidco Limited is a live company located in london, SE1 1PP with a Companies House number of 12674221. It operates in the activities of other holding companies n.e.c. sector, SIC Code 64209. Founded in June 2020, it's largest shareholder is value demonstration uk holdings limited with a 100% stake. Pharma Value Demonstration Bidco Limited is a young, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharma Value Demonstration Bidco Limited Health Check
Pomanda's financial health check has awarded Pharma Value Demonstration Bidco Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 3 areas for improvement. Company Health Check FAQs
0 Strong
1 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Pharma Value Demonstration Bidco Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (104)
- Pharma Value Demonstration Bidco Limited
- - Industry AVG
Pay Structure
on an average salary of £44.7k, the company has an equivalent pay structure (£44.7k)
- Pharma Value Demonstration Bidco Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Pharma Value Demonstration Bidco Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 1 weeks, this is less cash available to meet short term requirements (14 weeks)
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 85.3%, this is a higher level of debt than the average (69.6%)
- - Pharma Value Demonstration Bidco Limited
- - Industry AVG
PHARMA VALUE DEMONSTRATION BIDCO LIMITED financials
Pharma Value Demonstration Bidco Limited's latest turnover from December 2023 is 0 and the company has net assets of £43.5 million. According to their latest financial statements, we estimate that Pharma Value Demonstration Bidco Limited has 1 employee and maintains cash reserves of £2.7 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Turnover | ||||
| Other Income Or Grants | ||||
| Cost Of Sales | ||||
| Gross Profit | ||||
| Admin Expenses | ||||
| Operating Profit | 1,977,844 | 1,982,283 | -2,060,947 | 3,462,182 |
| Interest Payable | 30,223,712 | 16,303,729 | 6,819,550 | 1,552,321 |
| Interest Receivable | 14,947,522 | 11,805,814 | 2,915,641 | 482,530 |
| Pre-Tax Profit | -13,298,346 | 5,037,456 | 41,531,436 | 2,392,391 |
| Tax | 2,394,639 | -238,281 | 1,133,323 | -468,804 |
| Profit After Tax | -10,903,707 | 4,799,175 | 42,664,759 | 1,923,587 |
| Dividends Paid | 39,425,266 | |||
| Retained Profit | -10,903,707 | -34,626,091 | 42,664,759 | 1,923,587 |
| Employee Costs | ||||
| Number Of Employees | ||||
| EBITDA* | 1,977,844 | 1,982,283 | -2,060,947 | 3,462,182 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Tangible Assets | ||||
| Intangible Assets | ||||
| Investments & Other | 178,838,290 | 178,838,290 | 178,838,290 | 178,838,290 |
| Debtors (Due After 1 year) | 3,634,609 | 6,352,536 | ||
| Total Fixed Assets | 182,472,899 | 185,190,826 | 178,838,290 | 178,838,290 |
| Stock & work in progress | ||||
| Trade Debtors | ||||
| Group Debtors | 107,313,426 | 102,860,225 | 87,185,265 | 37,236,009 |
| Misc Debtors | 4,478,689 | 3,930,282 | 4,766,067 | 2,511,409 |
| Cash | 2,723,301 | 886,905 | 212,980 | |
| misc current assets | ||||
| total current assets | 114,515,416 | 107,677,412 | 92,164,312 | 39,747,418 |
| total assets | 296,988,315 | 292,868,238 | 271,002,602 | 218,585,708 |
| Bank overdraft | ||||
| Bank loan | 20,283,752 | 3,000,000 | ||
| Trade Creditors | ||||
| Group/Directors Accounts | 69,789,460 | 74,600,323 | 71,283,735 | 111,548,735 |
| other short term finances | ||||
| hp & lease commitments | ||||
| other current liabilities | 1,611,884 | 31,452 | 917,127 | 1,320,861 |
| total current liabilities | 91,685,096 | 77,631,775 | 72,200,862 | 112,869,596 |
| loans | 161,226,498 | 162,297,002 | 112,185,575 | 61,764,706 |
| hp & lease commitments | ||||
| Accruals and Deferred Income | ||||
| other liabilities | ||||
| provisions | 531,794 | 949,377 | ||
| total long term liabilities | 161,758,292 | 163,246,379 | 112,185,575 | 61,764,706 |
| total liabilities | 253,443,388 | 240,878,154 | 184,386,437 | 174,634,302 |
| net assets | 43,544,927 | 51,990,084 | 86,616,165 | 43,951,406 |
| total shareholders funds | 43,544,927 | 51,990,084 | 86,616,165 | 43,951,406 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Operating Profit | 1,977,844 | 1,982,283 | -2,060,947 | 3,462,182 |
| Depreciation | ||||
| Amortisation | ||||
| Tax | 2,394,639 | -238,281 | 1,133,323 | -468,804 |
| Stock | ||||
| Debtors | 2,283,681 | 21,191,711 | 52,203,914 | 39,747,418 |
| Creditors | ||||
| Accruals and Deferred Income | 1,580,432 | -885,675 | -403,734 | 1,320,861 |
| Deferred Taxes & Provisions | -417,583 | 949,377 | ||
| Cash flow from operations | 3,251,651 | -19,384,007 | -53,535,272 | -35,433,179 |
| Investing Activities | ||||
| capital expenditure | ||||
| Change in Investments | 178,838,290 | |||
| cash flow from investments | ||||
| Financing Activities | ||||
| Bank loans | 17,283,752 | 3,000,000 | ||
| Group/Directors Accounts | -4,810,863 | 3,316,588 | -40,265,000 | 111,548,735 |
| Other Short Term Loans | ||||
| Long term loans | -1,070,504 | 50,111,427 | 50,420,869 | 61,764,706 |
| Hire Purchase and Lease Commitments | ||||
| other long term liabilities | ||||
| share issue | ||||
| interest | -15,276,190 | -4,497,915 | -3,903,909 | -1,069,791 |
| cash flow from financing | -1,415,255 | 51,930,110 | 6,251,960 | 214,271,469 |
| cash and cash equivalents | ||||
| cash | 1,836,396 | 673,925 | 212,980 | |
| overdraft | ||||
| change in cash | 1,836,396 | 673,925 | 212,980 |
pharma value demonstration bidco limited Credit Report and Business Information
Pharma Value Demonstration Bidco Limited Competitor Analysis
Perform a competitor analysis for pharma value demonstration bidco limited by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other young companies, companies in SE1 area or any other competitors across 12 key performance metrics.
pharma value demonstration bidco limited Ownership
PHARMA VALUE DEMONSTRATION BIDCO LIMITED group structure
Pharma Value Demonstration Bidco Limited has 1 subsidiary company.
Ultimate parent company
ARSENAL CAPITAL PARTNERS V LP
#0030621
2 parents
PHARMA VALUE DEMONSTRATION BIDCO LIMITED
12674221
1 subsidiary
pharma value demonstration bidco limited directors
Pharma Value Demonstration Bidco Limited currently has 6 directors. The longest serving directors include Mr Stephen McLean (Jun 2020) and Mr Michael Bernstein (Jun 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Stephen McLean | United States | 67 years | Jun 2020 | - | Director |
| Mr Michael Bernstein | England | 64 years | Jun 2020 | - | Director |
| Mr Eugene Gorbach | England | 47 years | Jun 2020 | - | Director |
| Mr Jon Williams | England | 49 years | Jun 2020 | - | Director |
| Mr Jon Williams | England | 49 years | Jun 2020 | - | Director |
| M Michael Madden | United Kingdom | 46 years | Dec 2023 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
2m
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
43.5m
-0.16%
total assets
297m
+0.01%
cash
2.7m
+2.07%
net assets
Total assets minus all liabilities
Similar Companies
pharma value demonstration bidco limited company details
company number
12674221
Type
Private limited with Share Capital
industry
64209 - Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
incorporation date
June 2020
age
5
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
-
address
great suffolk yard, 127-131 great suffolk street, london, SE1 1PP
Bank
THE ROYAL BANK OF SCOTLAND PLC
Legal Advisor
-
pharma value demonstration bidco limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to pharma value demonstration bidco limited. Currently there are 1 open charges and 0 have been satisfied in the past.
pharma value demonstration bidco limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMA VALUE DEMONSTRATION BIDCO LIMITED. This can take several minutes, an email will notify you when this has completed.
pharma value demonstration bidco limited Companies House Filings - See Documents
| date | description | view/download |
|---|
